scout

Richard Finn, MD

Articles by Richard Finn, MD

CheckMate 9DW Study Results and Use of Ipiimumab/Nivolumab in First- and Second-Line Treatment

ByRichard Finn, MD,Olatunji Alese, MD,Daneng Li, MD,Anthony El-Khoueiry, MD,Masatoshi Kudo, MD, PhD,Steven Chan, MD

Panelists discuss key updates from the 2024 American Society of Clinical Oncology Annual Meeting and the European Society for Medical Oncology Congress 2024 regarding treatments for unresectable hepatocellular carcinoma (uHCC), including insights from the CheckMmate 9DW study on the use of nivolumab and ipilimumab, and their implications for sequencing and combination therapies in various lines of treatment.

Importance of Real-World Data in Supporting Treatment Options

ByRichard Finn, MD,Olatunji Alese, MD,Daneng Li, MD,Anthony El-Khoueiry, MD,Masatoshi Kudo, MD, PhD,Steven Chan, MD

Panelists discuss the insights from real-world data on the effectiveness of cabozantinib, regorafenib, and ramucirumab in second-line treatment for unresectable hepatocellular carcinoma, highlighting the differences between strict eligibility criteria and more flexible modified criteria in patient selection.

Discussion of LEAP-012 and EMERALD-1 Study Results and Appropriate Sequencing

ByRichard Finn, MD,Olatunji Alese, MD,Daneng Li, MD,Anthony El-Khoueiry, MD,Masatoshi Kudo, MD, PhD,Steven Chan, MD

Panelists discuss the findings from the EMERALD-1 trial on durvalumab with or without bevacizumab combined with transarterial chemoembolization TACE for first-line treatment of unresectable hepatocellular carcinomaHCC, examining its implications on progression-free survival, safety, and outcomes based on baseline tumor burden.

Latest Updated Articles